- Home
- EVT vs IMCR Comparison
EVT vs IMCR Comparison
Compare EVT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVT | IMCR |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2003 | 2016 |
Fundamental Metrics
Financial Performance| Metric | EVT | IMCR |
|---|---|---|
| Price | $25.44 | $31.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $61.82 |
| AVG Volume (30 Days) | 102.8K | ★ 392.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | N/A | $8.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $20.56 | $26.37 |
| 52 Week High | $26.65 | $40.71 |
Technical Indicators
Market Signals| Indicator | EVT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 47.50 |
| Support Level | $23.98 | $28.90 |
| Resistance Level | $25.92 | $31.65 |
| Average True Range (ATR) | 0.46 | 1.16 |
| MACD | 0.17 | 0.24 |
| Stochastic Oscillator | 96.59 | 51.40 |
Price Performance
Historical ComparisonAbout EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.